LUX Lung Special Access Scheme Australia Named Patient Use (NPU)
The program will provide early access to the investigational drug BIBW 2992 to treat patients with advanced NSCLC who have failed at least 12 weeks on erlotinib or gefitinib.
The Compassionate Use Programme will also provide additional safety and efficacy information on BIBW 2992 use.
Named Patient Use (NPU)
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Expanded Access Program BIBW 2992 for Non Small Cell Lung Cancer ( NSCLC) Last Line Treatment|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01209650
|Australia, New South Wales|
|1200.47.1 Boehringer Ingelheim Investigational Site|
|North Ryde, New South Wales, Australia|
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|